Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An interpretation of the EBCTCG data.

Jerry P Lewis1

  • 1Department of Medicine, University of California, Davis, USA. jerrymarguerite@comcast.net

The Oncologist
|May 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The case for per patient payments.

IRB·1988
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same journal

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.

The oncologist·2026
Same journal

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

The oncologist·2026
See all related articles

Adjuvant hormonal and polychemotherapy therapies primarily impact early-emerging breast cancer tumors during treatment. While benefits accrue during administration, recurrence reduction is maintained long-term, suggesting a potential carryover effect.

Area of Science:

  • Oncology
  • Clinical Trials
  • Breast Cancer Research

Background:

  • Adjuvant therapies are crucial in reducing breast cancer recurrence.
  • Understanding the timing and duration of treatment benefits is essential for optimizing patient outcomes.

Purpose of the Study:

  • To analyze published data on adjuvant hormonal and polychemotherapy for early breast cancer.
  • To investigate the temporal pattern of benefit accrual and long-term effects of these therapies.

Main Methods:

  • Review and interpretation of published data and figures from the Early Breast Cancer Clinical Trialists' Collaborative Group.
  • Analysis of the timing of benefit in relation to drug administration and recurrence reduction.

Main Results:

Related Experiment Videos

  • The primary impact of adjuvant therapies appears concentrated on soon-to-emerge tumors during the treatment period.
  • Benefits in reducing recurrence, once achieved, are sustained over many years.
  • The accrual of benefits is largely confined to the duration of drug administration.

Conclusions:

  • Adjuvant hormonal and polychemotherapy demonstrate a time-limited impact during administration, primarily affecting early-stage tumors.
  • Sustained long-term reduction in recurrence suggests a lasting benefit, potentially indicating a carryover effect.
  • Further investigation is warranted to fully elucidate the carryover effect of adjuvant therapies in breast cancer management.